JYB1907 in Subjects With Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2024-10-31
• Target enrollment: 0
• Participant gender: All

Summary

A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid Tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jemincare

Criteria

Inclusion Criteria:

1. Able to provide written informed consent voluntarily;

2. Age ≥18, male or female;

3. Have at least one evaluable lesion (Dose escalation) or measurable lesion;

4. Expected survival ≥12 weeks；

5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;

Exclusion Criteria:

1. Received within 4 weeks before the initial treatment, or scheduled during the study to receive a major surgery, live attenuated vaccines, or any anti-tumor therapy.

2. With severe tumor complications.

3. Pregnant or lactating women, or positive serum pregnancy test;

4. Concurrent participation in another interventional study；

5. With other diseases or clinical abnormalities assessed by the Investigator as ineligible.